Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Genetics

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 30 articles:
HTML format



Single Articles


    July 2020
  1. HORNIGOLD N, Dunn KR, Craven RA, Zougman A, et al
    Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion.
    Br J Cancer. 2020;123:137-147.
    PubMed     Abstract available


    May 2020
  2. FORD CE, Werner B, Hacker NF, Warton K, et al
    The untapped potential of ascites in ovarian cancer research and treatment.
    Br J Cancer. 2020 May 8. pii: 10.1038/s41416-020-0875.
    PubMed     Abstract available


    March 2020
  3. LUCA BA, Moulton V, Ellis C, Edwards DR, et al
    A novel stratification framework for predicting outcome in patients with prostate cancer.
    Br J Cancer. 2020 Mar 20. pii: 10.1038/s41416-020-0799.
    PubMed     Abstract available


  4. POWLEY IR, Patel M, Miles G, Pringle H, et al
    Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
    Br J Cancer. 2020;122:735-744.
    PubMed     Abstract available


    February 2020
  5. NIEGISCH G
    Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
    Br J Cancer. 2020;122:453-454.
    PubMed     Abstract available


  6. VISSIO E, Metovic J, Osella-Abate S, Bertero L, et al
    Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
    Br J Cancer. 2020;122:382-387.
    PubMed     Abstract available


    January 2020
  7. WHITWELL HJ, Worthington J, Blyuss O, Gentry-Maharaj A, et al
    Improved early detection of ovarian cancer using longitudinal multimarker models.
    Br J Cancer. 2020 Jan 15. pii: 10.1038/s41416-019-0718.
    PubMed     Abstract available


    August 2019
  8. KORPHAISARN K, Morris V, Davis JS, Overman MJ, et al
    Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
    Br J Cancer. 2019 Aug 13. pii: 10.1038/s41416-019-0548.
    PubMed     Abstract available


    July 2019
  9. BRAR G, Blais EM, Joseph Bender R, Brody JR, et al
    Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.
    Br J Cancer. 2019;121:264-270.
    PubMed     Abstract available


  10. WILLEMSEN AECAB, Krausz S, Ligtenberg MJL, Grunberg K, et al
    Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
    Br J Cancer. 2019;121:34-36.
    PubMed     Abstract available


    April 2019
  11. IACHETTA F, Bonelli C, Romagnani A, Zamponi R, et al
    The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study.
    Br J Cancer. 2019;120:834-839.
    PubMed     Abstract available


    March 2019
  12. GIOVANNINI C, Salzano AM, Baglioni M, Vitale M, et al
    Brivanib in combination with Notch3 silencing shows potent activity in tumour models.
    Br J Cancer. 2019;120:601-611.
    PubMed     Abstract available


    October 2018
  13. WILLIAMS LA, Mills L, Hooten AJ, Langer E, et al
    Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0277.
    PubMed     Abstract available


  14. WANG P, Magdolen V, Seidl C, Dorn J, et al
    Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0260.
    PubMed     Abstract available


    August 2018
  15. KRISP C, Parker R, Pascovici D, Hayward NK, et al
    Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
    Br J Cancer. 2018 Aug 17. pii: 10.1038/s41416-018-0227.
    PubMed     Abstract available


    July 2018
  16. SAHA A, Harowicz MR, Grimm LJ, Kim CE, et al
    A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0185.
    PubMed     Abstract available


    March 2018
  17. SHINOZAKI E, Yoshino T, Tsuchihara K
    Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Ant
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0040.
    PubMed    


  18. DANKNER M, Rose AAN
    Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0012.
    PubMed    


  19. EL ANSARI R, Craze ML, Diez-Rodriguez M, Nolan CC, et al
    The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
    Br J Cancer. 2018 Mar 16. pii: 10.1038/s41416-018-0038.
    PubMed     Abstract available


    November 2017
  20. ZHANG J, Hao N, Liu W, Lu M, et al
    In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery.
    Br J Cancer. 2017;117:1676-1684.
    PubMed     Abstract available


    October 2017
  21. RUZZO A, Graziano F, Galli F, Galli F, et al
    Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
    Br J Cancer. 2017;117:1269-1277.
    PubMed     Abstract available


  22. SHINOZAKI E, Yoshino T, Yamazaki K, Muro K, et al
    Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensi
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    August 2017
  23. LEVI F, Karaboue A, Saffroy R, Desterke C, et al
    Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    July 2017
  24. SARASWAT M, Makitie A, Agarwal R, Joenvaara S, et al
    Oral squamous cell carcinoma patients can be differentiated from healthy individuals with label-free serum proteomics.
    Br J Cancer. 2017;117:376-384.
    PubMed     Abstract available


    June 2017
  25. ALVI MA, Loughrey MB, Dunne P, McQuaid S, et al
    Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.
    Br J Cancer. 2017 Jun 8. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    April 2017
  26. HEQUET D, Huchon C, Baffert S, Alran S, et al
    Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators.
    Br J Cancer. 2017 Apr 25. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    January 2017
  27. HU H, Shu M, He L, Yu X, et al
    Epigenomic landscape of 5-hydroxymethylcytosine reveals its transcriptional regulation of lncRNAs in colorectal cancer.
    Br J Cancer. 2017 Jan 31. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    November 2016
  28. GROSSI F, Rijavec E, Genova C, Barletta G, et al
    Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    September 2016
  29. LARKIN SE, Johnston HE, Jackson TR, Jamieson DG, et al
    Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.
    Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    May 2016
  30. MESEURE D, Vacher S, Lallemand F, Alsibai KD, et al
    Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.
    Br J Cancer. 2016 May 12. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Genetics is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: